35700-21-1

Basic information

• Product Name: 15(S)-15-Methyl prostaglandin
• Synonyms: 9ALPHA,11ALPHA,15S-TRIHYDROXY-15-METHYL-PROSTA-5Z,13E-DIEN-1-OIC ACID, METHYL ESTER;15(S)-15-methylProstaglandinF2amethylester;15(S)-15-methylProstaglandinF2αmethylester;15(S)-15-METHYL PROSTAGLANDIN;Carboprost methyl ester;Methyl (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoate;U-36384;15(s)15-methyl-pgf2-alphamethylester
• CAS NO: 35700-21-1
• Molecular Formula: C₂₂H₃₈O₅
• Molecular Weight: 382.53
• Mol File: 35700-21-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 55-56°
• Boiling Point: 429.67°C (rough estimate)
• Flash Point: 162.2 °C
• Appearance: /
• Density: 1.0323 (rough estimate)
• Vapor Pressure: 3.62E-12mmHg at 25°C
• Refractive Index: 1.6120 (estimate)
• CAS DataBase Reference: 15(S)-15-Methyl prostaglandin(CAS DataBase Reference)
• NIST Chemistry Reference: 15(S)-15-Methyl prostaglandin(35700-21-1)
• EPA Substance Registry System: 15(S)-15-Methyl prostaglandin(35700-21-1)

Safety Data

• Hazardous Substances Data: 35700-21-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 35700-21-1 differently. You can refer to the following data:
1. 15(S)-15-methyl PGF2α methyl ester is a derivative of 15(S)-15-methyl PGF2α with increased membrane permeability. Hydrolysis of the methyl ester in vivo releases the biologically active 15(S)-15-methyl PGF2α, which is a potent uterine stimulant and abortifacient.
2. Carboprost Methyl Ester, used in combination with Misoprostol (M368755), can boost human preadipocyte proliferation, glycerolphosphate dehrydogenase (GPDH) up-regulation and lipid accumulation during differentiation. Also, mice treated with Carboprost Methyl Ester showed termination of early pregnancy and peristatic effects. This compound is suitable for pyruvate dehydrogenase (PDH) related research.

InChI:InChI=1/C22H38O5/c1-4-5-10-14-22(2,26)15-13-18-17(19(23)16-20(18)24)11-8-6-7-9-12-21(25)27-3/h6,8,13,15,17-20,23-24,26H,4-5,7,9-12,14,16H2,1-3H3/b8-6+,15-13-/t17-,18?,19+,20-,22-/m0/s1

Upstream product

• 41691-84-3 (5Z,9α,11α,13E)-15-methyl-9,11,15-trihydroxy-prosta-5,13-diene-1-carboxylic acid 
• 74-88-4 methyl iodide 
• 35700-23-3 Carboprost 
• 31753-00-1 [1,1'-bisphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-1-octen-1-yl]-2H-cyclopenta[b]furan-5-yl ester 
• 42743-23-7 [1,1'-bisphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-hydroxy-3-methyl-1-octen-1-yl]-2H-cyclopenta[b]furan-5-yl ester 

Downstream Products

• 35700-23-3 Carboprost 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF CARBOPROST AND ITS TROMETHAMINE SALT

The subject of the invention is a novel process for the preparation of Carboprost tromethamine salt where alkylation the enone of the general formula (II) is carried out in the presence of a chiral auxiliary in aprotic solvent with a Grignard reagent. The methyl ester epimers of formula (VII) are separated by gravity silicagel chromatography and the salt formation is carried out by using solid tromethamine base.

8β,12α,15β-PGF2 β Compounds

This invention is a group of 8-beta, 12-alpha-PG2 (prostaglandin-type) analogs having variable chain length, or methyl or phenyl substitution in the hydroxy-substituted side-chain, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, and labor inducement at term.